Berliner Boersenzeitung - Treatment improves cognition in Down Syndrome patients

EUR -
AED 4.021503
AFN 73.974597
ALL 98.722789
AMD 422.669128
ANG 1.970756
AOA 999.073261
ARS 1065.84545
AUD 1.62179
AWG 1.971313
AZN 1.865626
BAM 1.955657
BBD 2.207839
BDT 130.670456
BGN 1.955539
BHD 0.41227
BIF 3225.864382
BMD 1.09487
BND 1.428296
BOB 7.583446
BRL 6.144196
BSD 1.09352
BTN 91.900888
BWP 14.51194
BYN 3.578539
BYR 21459.452596
BZD 2.204139
CAD 1.507253
CDF 3151.036344
CHF 0.938544
CLF 0.03677
CLP 1018.515607
CNY 7.736575
CNH 7.74406
COP 4594.964383
CRC 564.858743
CUC 1.09487
CUP 29.014056
CVE 110.256947
CZK 25.320626
DJF 194.715778
DKK 7.468879
DOP 65.835191
DZD 145.736004
EGP 53.12012
ERN 16.42305
ETB 130.945336
FJD 2.431492
FKP 0.837761
GBP 0.837761
GEL 2.972616
GGP 0.837761
GHS 17.468695
GIP 0.837761
GMD 75.002813
GNF 9455.297972
GTQ 8.470972
GYD 229.203488
HKD 8.507009
HNL 27.186048
HRK 7.542593
HTG 144.340375
HUF 401.69729
IDR 17046.195734
ILS 4.115431
IMP 0.837761
INR 92.126293
IQD 1433.732305
IRR 46096.769633
ISK 149.614412
JEP 0.837761
JMD 173.444435
JOD 0.77572
JPY 163.287865
KES 141.238618
KGS 93.615547
KHR 4450.647057
KMF 492.144285
KPW 985.383411
KRW 1477.330449
KWD 0.335611
KYD 0.912922
KZT 530.419678
LAK 23955.756647
LBP 98045.611605
LKR 320.681494
LRD 211.090958
LSL 19.149694
LTL 3.232867
LVL 0.662276
LYD 5.249945
MAD 10.733563
MDL 19.235343
MGA 5019.979469
MKD 61.721903
MMK 2297.037703
MNT 3720.368742
MOP 8.768618
MRU 43.521498
MUR 50.473509
MVR 16.806669
MWK 1900.69475
MXN 21.108366
MYR 4.69426
MZN 69.962187
NAD 19.14969
NGN 1795.587226
NIO 40.324475
NOK 11.711546
NPR 147.31642
NZD 1.792107
OMR 0.420919
PAB 1.09487
PEN 4.110803
PGK 4.305303
PHP 62.65941
PKR 304.100561
PLN 4.294387
PYG 8550.309019
QAR 3.986536
RON 4.980021
RSD 117.083977
RUB 104.753153
RWF 1483.548891
SAR 4.111472
SBD 9.04913
SCR 14.87092
SDG 658.568348
SEK 11.355384
SGD 1.429029
SHP 0.837761
SLE 25.014827
SLL 22958.881115
SOS 625.171157
SRD 34.97727
STD 22661.599096
SVC 9.58638
SYP 2750.894202
SZL 19.054736
THB 36.242353
TJS 11.678367
TMT 3.842994
TND 3.362387
TOP 2.584335
TRY 37.53401
TTD 7.436211
TWD 35.194596
TZS 2985.235164
UAH 45.113294
UGX 4026.27158
USD 1.09487
UYU 45.702439
UZS 14003.388055
VEF 3966224.203526
VES 42.301013
VND 27174.749005
VUV 129.985201
WST 3.069587
XAF 656.208756
XAG 0.034703
XAU 0.000412
XCD 2.958941
XDR 0.81497
XOF 656.208756
XPF 119.331742
YER 274.100784
ZAR 19.061233
ZMK 9855.148044
ZMW 28.94922
ZWL 352.547703
  • BCC

    3.4200

    142.37

    +2.4%

  • BCE

    0.1600

    33.02

    +0.48%

  • CMSC

    0.1200

    24.71

    +0.49%

  • GSK

    -0.3800

    38.83

    -0.98%

  • AZN

    0.4800

    77.35

    +0.62%

  • SCS

    0.3100

    12.91

    +2.4%

  • RBGPF

    1.7400

    61.23

    +2.84%

  • JRI

    0.0300

    13.25

    +0.23%

  • CMSD

    0.1800

    24.95

    +0.72%

  • RIO

    0.3900

    67.23

    +0.58%

  • NGG

    0.5600

    66.24

    +0.85%

  • RELX

    0.4700

    46.83

    +1%

  • VOD

    -0.0900

    9.65

    -0.93%

  • RYCEF

    0.0100

    7.01

    +0.14%

  • BTI

    0.0700

    35.18

    +0.2%

  • BP

    -0.2300

    32.11

    -0.72%

Treatment improves cognition in Down Syndrome patients
Treatment improves cognition in Down Syndrome patients / Photo: Andreas SOLARO - AFP/File

Treatment improves cognition in Down Syndrome patients

A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.

Text size:

However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.

"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.

Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.

Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.

Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.

GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.

"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.

- Mice research -

The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.

They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.

The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.

A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.

They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.

Cognition and smell tests were carried out during the treatment, as were MRI scans.

Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.

"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.

The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.

- 'Improve quality of life' -

The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".

"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.

A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.

"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.

Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".

He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.

It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.

"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."

(K.Lüdke--BBZ)